CymaBay Therapeutics’ (CBAY) Buy Rating Reaffirmed at HC Wainwright

CymaBay Therapeutics (NASDAQ:CBAY)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday, MarketBeat reports. They presently have a $18.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $12.00. HC Wainwright’s price objective suggests a potential upside of 54.64% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Leerink Swann reaffirmed a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Oppenheimer set a $15.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $16.00 price objective on shares of CymaBay Therapeutics in a research note on Wednesday, November 8th. Zacks Investment Research cut CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $12.00 price objective on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. CymaBay Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.56.

CymaBay Therapeutics (NASDAQ CBAY) traded down $0.20 on Wednesday, hitting $11.64. The stock had a trading volume of 622,862 shares, compared to its average volume of 626,488. The company has a market capitalization of $510.58, a PE ratio of -11.52 and a beta of 1.82. CymaBay Therapeutics has a 1 year low of $1.60 and a 1 year high of $12.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39.

CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same quarter in the previous year, the company earned ($0.25) earnings per share. sell-side analysts expect that CymaBay Therapeutics will post -0.83 EPS for the current year.

In other CymaBay Therapeutics news, Director Kurt Von Emster sold 39,438 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $12.18, for a total transaction of $480,354.84. Following the completion of the sale, the director now owns 90,000 shares in the company, valued at $1,096,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Charles Mcwherter bought 5,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were bought at an average price of $8.67 per share, with a total value of $43,350.00. Following the acquisition, the senior vice president now owns 10,300 shares of the company’s stock, valued at $89,301. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 626,656 shares of company stock valued at $6,238,232. 15.10% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC purchased a new stake in shares of CymaBay Therapeutics during the 3rd quarter valued at $18,948,000. Citadel Advisors LLC acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at $5,159,000. EAM Investors LLC acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at $4,788,000. Omega Fund Management LLC increased its position in shares of CymaBay Therapeutics by 82.9% in the 3rd quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock valued at $4,445,000 after acquiring an additional 250,000 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at $1,536,000. Institutional investors own 69.12% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/28/cymabay-therapeutics-cbay-buy-rating-reaffirmed-at-hc-wainwright.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply